Nachrichten zur Marker Therapeutics Inc. Aktie

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…

AKRO INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO

NEW ORLEANS, April 30, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former…

AKERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. (AKRO)

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action…

AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Akero Class Action Lawsuit

SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that it has…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant…

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on…

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…